Atea Pharmaceuticals Announces US FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19

Atea Pharmaceuticals, Inc. announced that the US FDA has granted Fast Track designation to bemnifosbuvir, an oral direct-acting antiviral drug candidate, for the global Phase III SUNRISE-3 registrational trial for the treatment of COVID-19.